These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23167930)

  • 1. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
    Svoboda M; Sana J; Fabian P; Kocakova I; Gombosova J; Nekvindova J; Radova L; Vyzula R; Slaby O
    Radiat Oncol; 2012 Nov; 7():195. PubMed ID: 23167930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Della Vittoria Scarpati G; Falcetta F; Carlomagno C; Ubezio P; Marchini S; De Stefano A; Singh VK; D'Incalci M; De Placido S; Pepe S
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1113-9. PubMed ID: 22172905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy.
    Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M
    Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Wang L; Li ZY; Li ZW; Li YH; Sun YS; Ji JF; Gu J; Cai Y
    Dis Colon Rectum; 2015 Feb; 58(2):186-92. PubMed ID: 25585076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
    Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Becker H; Baretton GB; Aust DE
    World J Gastroenterol; 2008 Feb; 14(7):1060-6. PubMed ID: 18286688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
    Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
    Marsh Rde W; George TJ; Siddiqui T; Mendenhall WM; Zlotecki RA; Grobmyer S; Hochwald S; Chang M; Larson B; King J
    Am J Clin Oncol; 2010 Jun; 33(3):251-6. PubMed ID: 19823074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
    Richter I; Dvořák J; Blüml A; Cermáková E; Bartoš J; Urbanec M; Sitorová V; Ryška A; Sirák I; Buka D; Ferko A; Melichar B; Petera J
    Klin Onkol; 2014; 27(5):361-6. PubMed ID: 25312714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
    Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
    Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer].
    Tamura A; Ami K; Watanabe A; Hayasaka J; Takagi K; Okamoto E; Kitazume A; Kondou M; Gokita K; Imai K; Tei S; Ando M; Arai K; Shibayama T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1566-8. PubMed ID: 25731254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
    Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
    Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
    Kocakova I; Svoboda M; Kubosova K; Chrenko V; Roubalova E; Krejci E; Sefr R; Slampa P; Frgala T; Zaloudik J
    Neoplasma; 2007; 54(5):447-53. PubMed ID: 17688376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.
    Sebio A; Salazar J; Páez D; Berenguer-Llergo A; Del Río E; Tobeña M; Martín-Richard M; Sullivan I; Targarona E; Balart J; Baiget M; Barnadas A
    Pharmacogenomics J; 2015 Feb; 15(1):77-83. PubMed ID: 25026457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
    Bibby BA; Reynolds JV; Maher SG
    PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.